Try our beta test site
IMPORTANT: Listing of a study on this site does not reflect endorsement by the National Institutes of Health. Talk with a trusted healthcare professional before volunteering for a study. Read more...

Flavopiridol, Cytarabine, and Mitoxantrone in Treating Patients With Acute Leukemia

This study has been completed.
Information provided by (Responsible Party):
National Cancer Institute (NCI) Identifier:
First received: May 6, 2001
Last updated: October 7, 2013
Last verified: October 2013
Phase II trial to study the effectiveness of combining flavopiridol and cytarabine with mitoxantrone in treating patients who have acute leukemia. Drugs used in chemotherapy work in different ways to stop cancer cells from dividing so they stop growing or die. Combining more than one drug may kill more cancer cells.

Condition Intervention Phase
Recurrent Adult Acute Lymphoblastic Leukemia
Recurrent Adult Acute Myeloid Leukemia
Secondary Acute Myeloid Leukemia
Untreated Adult Acute Lymphoblastic Leukemia
Untreated Adult Acute Myeloid Leukemia
Drug: cytarabine
Drug: mitoxantrone hydrochloride
Drug: alvocidib
Other: pharmacological study
Other: laboratory procedure
Phase 1
Phase 2

Study Type: Interventional
Study Design: Intervention Model: Single Group Assignment
Masking: Open Label
Primary Purpose: Treatment
Official Title: A Phase I/II Study of Flavopiridol (NSC 649890, IND 46,211) in Timed Sequential Combination With Cytosine Arabinoside (Ara-C) and Mitoxantrone for Adults With Poor-Risk Acute Leukemias

Resource links provided by NLM:

Further study details as provided by National Cancer Institute (NCI):

Primary Outcome Measures:
  • Dose-limiting toxicity (DLT) as assessed by NCI CTC version 2.0 [ Time Frame: Up to 35 days ]
  • Complete remission (CR) [ Time Frame: Up to 6 years ]

Estimated Enrollment: 53
Study Start Date: February 2001
Primary Completion Date: November 2006 (Final data collection date for primary outcome measure)
Arms Assigned Interventions
Experimental: Treatment (flavopiridol, cytarabine, mitoxantrone)
Patients receive flavopiridol IV over 1 hour on days 1-3 and cytarabine IV continuously on days 6-9 followed by mitoxantrone IV over 30-150 minutes on day 9. Patients achieving a partial or complete response after the first course of therapy may receive an additional course of therapy beginning 35 ± 7 days after blood count recovery.
Drug: cytarabine
Given IV
Drug: mitoxantrone hydrochloride
Given IV
Drug: alvocidib
Given IV
Other: pharmacological study
Correlative studies
Other: laboratory procedure
Correlative studies

Detailed Description:


I. To determine the toxicities of escalating doses of flavopiridol administered in a timed sequence with ara-C and mitoxantrone in adults with refractory or relapsed acute leukemias or high-risk myelodysplasias (MDS).

II. To determine if flavopiridol administered in a timed sequence with ara-C and Mitoxantrone will induce clinical responses in adults with refractory or relapsed acute leukemias or MDS.

III. To determine if flavopiridol is directly cytotoxic to leukemic blasts in vivo.

IV. To determine if flavopiridol can recruit and synchronize residual leukemic blasts to proliferate in vivo.

OUTLINE: This is a dose-escalation study of flavopiridol. (Phase I closed to accrual effective10/24/2003).

Patients receive flavopiridol IV over 1 hour on days 1-3 and cytarabine IV continuously on days 6-9 followed by mitoxantrone IV over 30-150 minutes on day 9. Patients achieving a partial or complete response after the first course of therapy may receive an additional course of therapy beginning 35 ± 7 days after blood count recovery.

Cohorts of 3-6 patients receive escalating doses of flavopiridol until the maximum tolerated dose (MTD) is determined. The MTD is defined as the dose preceding that at which at least 2 of 3 or 2 of 6 patients experience dose-limiting toxicity. (Phase I closed to accrual effective 10/24/2003). Once the MTD is reached, additional patients are accrued to receive flavopiridol at the recommended phase II dose.


Ages Eligible for Study:   18 Years and older   (Adult, Senior)
Sexes Eligible for Study:   All
Accepts Healthy Volunteers:   No

Inclusion Criteria:

  • Established diagnoses of poor-risk hematologic malignancies will be considered eligible for this Phase I/II study
  • Pathological confirmation of the diagnosis of AML or ALL
  • ECOG performance status 0,1,2
  • Patients must be able to give informed consent
  • Female patients of childbearing age must have negative pregnancy test
  • AST and ALT =< 2.5 x normal
  • Alkaline phosphatase =< 2.5 x normal
  • Bilirubin =< 1.5 x normal
  • Serum creatinine =< 2.0 mg/dl
  • Left ventricular ejection fraction must >= 45% by MUGA or Echocardiogram
  • Acute Myelogenous Leukemia (AML)

    • AML arising from MDS
    • Secondary AML
    • Relapsed or refractory AML, including primary induction failure
  • Acute Lymphoblastic Leukemia (ALL)

    • Relapsed or refractory ALL, including primary induction failure
    • Patients who fail primary induction therapy or who relapse after achieving complete remission (CR) are eligible if they have undergone no more than 3 prior courses of induction/reinduction
  • There should be an interval of at least 4 weeks from any previous intensive chemotherapy before beginning flavopiridol, with the exceptions non-aplasia producing treatments (i.e. hydroxyurea, interferon, imatinib, 6MP, thalidomide); patients should have recovered completely from any treatment-related toxicities; patients may have received hematopoietic growth factors previously, but must be off all growth factors (including EPO, G-CSF, GM-CSF, IL-3, IL-11) for at least 4 days prior to beginning flavopiridol
  • Patients who have undergone stem cell transplantation (SCT), autologous or allogeneic, are eligible provided that they are >= 4 weeks from stem cell infusion, have no active GVHD, and meet other eligibility criteria

Exclusion Criteria:

  • Hyperleukocytosis with >= 50,000 leukemic blasts/mm^3
  • Active, uncontrolled infection
  • Disseminated intravascular coagulation
  • Active CNS leukemia
  • Concomitant chemotherapy, radiation therapy or immunotherapy
  • Intrinsic impaired cardiac function (MI within the preceding 3 months or history of severe coronary artery disease, cardiomyopathy, CHF > Class II)
  • History of congestive heart disease, or arrhythmia without regard to time, severity or resolution
  • Women who are pregnant or lactating will not be eligible for this trial, as the investigational agent may be harmful to the developing fetus or nursing infant
  Contacts and Locations
Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the Contacts provided below. For general information, see Learn About Clinical Studies.

Please refer to this study by its identifier: NCT00016016

United States, Maryland
Johns Hopkins University
Baltimore, Maryland, United States, 21287-8936
Sponsors and Collaborators
National Cancer Institute (NCI)
Principal Investigator: Judith Karp Johns Hopkins University
  More Information

Responsible Party: National Cancer Institute (NCI) Identifier: NCT00016016     History of Changes
Other Study ID Numbers: NCI-2012-03153
NCI-2012-03153 ( Registry Identifier: CTRP (Clinical Trial Reporting Program) )
J0254 ( Other Identifier: Johns Hopkins University )
3170 ( Other Identifier: CTEP )
U01CA070095 ( US NIH Grant/Contract Award Number )
U01CA069854 ( US NIH Grant/Contract Award Number )
Study First Received: May 6, 2001
Last Updated: October 7, 2013

Additional relevant MeSH terms:
Leukemia, Myeloid
Leukemia, Myeloid, Acute
Precursor Cell Lymphoblastic Leukemia-Lymphoma
Leukemia, Lymphoid
Neoplasms by Histologic Type
Lymphoproliferative Disorders
Lymphatic Diseases
Immunoproliferative Disorders
Immune System Diseases
Antimetabolites, Antineoplastic
Molecular Mechanisms of Pharmacological Action
Antineoplastic Agents
Antiviral Agents
Anti-Infective Agents
Immunosuppressive Agents
Immunologic Factors
Physiological Effects of Drugs
Sensory System Agents
Peripheral Nervous System Agents
Topoisomerase II Inhibitors
Topoisomerase Inhibitors
Enzyme Inhibitors
Growth Inhibitors processed this record on May 25, 2017